

From: s22
To: TGA FOI
Cc: s47
Subject: RE: FOI 26-2918 - Third Party Consultation - Maxx Pharma Pty Ltd [SEC=OFFICIAL]
Date: Monday, 18 May 2026 3:37:56 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[image006.png](#)
[Document 1 MR-FOI.pdf](#)

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear s22

Thank you for your email.

Please refer to the enclosed PDF for the proposed redactions and supporting rationale. The justification for each redaction is provided in the comments panel.

Please keep us updated on the progress of this request.

Regards,

s22

s47G

s22

ant, Regulatory, Quality & Compliance

Tel: s22

Work Location: Sydney (GMT+11)

s47G

From: TGA FOI <TGAFOI@health.gov.au>

Sent: Thursday, 14 May 2026 2:49 PM

To: s22 @s47G

Cc: s47G TGA FOI
<TGAFOI@health.gov.au>

Subject: RE: FOI 26-2918 - Third Party Consultation - Maxx Pharma Pty Ltd [SEC=OFFICIAL]

CAUTION: This email is external and originated from outside s47G. Do not click on links or open attachments unless you recognise the sender and sender's email address and know the content is safe.

OFFICIAL

Dear **s22**

Thank you for your response to the consultation on behalf of Maxx Pharma for FOI 26-2918.

The TGA delegate has considered your submission and has advised that they believe it is appropriate to redact information that is commercially sensitive such as manufacturing details, excipients, literature studies submitted noting that the application is currently under evaluation.

They have, however indicated that the information relating to pre-submission meetings, proposed indications, PO address and position of the Regulatory Affairs is in the public domain and as such does not consider them to be commercially sensitive or relate to personal/privacy.

Publicly available sources:

s47G

For consideration:

A copy of the document with redactions as proposed for release by the delegate is **attached** for your consideration. We would be grateful for your indication of whether you agree with these prior to a final decision being reached.

Your response would by **Monday, 18 May 2026** would be appreciated.

Should you have any questions or wish to discuss, please don't hesitate to contact the TGA FOI team. Thank you again for your time.

Kind regards

s22

Freedom of Information



Therapeutic Goods Administration

Australian Government Department of Health, Disability and Ageing

T: 02 6289 4630 | E: TGAFOI@health.gov.au

PO Box 100, Woden ACT 2606, Australia

Web: www.tga.gov.au

Important: *This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission.*

The Department of Health, Disability and Ageing acknowledges the Traditional Custodians of

Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

OFFICIAL

From: s22 @s47G
Sent: Monday, 4 May 2026 2:55 PM
To: TGA FOI <TGAFOI@health.gov.au>
Cc: s47G
Subject: RE: FOI 26-2918 - Third Party Consultation - Maxx Pharma Pty Ltd
[SEC=OFFICIAL]

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear s22

Thank you for your email.

We have reviewed the document and proposed redactions. The justification for each redaction is provided in the comments panel. Please refer to the enclosed PDF for the proposed redactions and supporting rationale.

Please keep us updated on the progress of this request.

Regards,

s22

s47G

s22

Tel: s22

gulatory, Quality & Compliance

Work Location: Sydney (GMT+11)

s47G

From: TGA FOI <TGAFOI@health.gov.au>

Sent: Tuesday, 28 April 2026 9:09 AM

To: s22 @s47G

Cc: TGA FOI <TGAFOI@health.gov.au>; s47G

s47G

Subject: FOI 26-2918 - Third Party Consultation - Maxx Pharma Pty Ltd [SEC=OFFICIAL]

Some people who received this message don't often get email from tgafoi@health.gov.au. [Learn why this is important](#)

CAUTION: This email is external and originated from outside s47G. Do not click on links or open attachments unless you recognise the sender and sender's email address and know the content is safe.

OFFICIAL

Dear s22

The TGA has received a Freedom of Information request under the *Freedom of Information Act 1982* (FOI Act) relating to Maxx Pharma Pty Ltd's pre-submission form for the registration of Cardioxane dextrazoxane s47. A document containing information regarding your business has been identified as falling within the scope of the request.

Please find attached correspondence for your consideration.

Disclosure Log Publication

The TGA is required under section 11C of the FOI Act to publish on its website, or otherwise make available, documents released to an applicant in response to an FOI request. The TGA publishes these documents on the FOI Disclosure Log at [FOI Disclosure Log | Therapeutic Goods Administration](#). You can find more information about the Disclosure Log at [OAIC FOI Guidelines | Disclosure Logs](#).

Action Required

As outlined in further detail in the attached letter, your views are sought in relation to release of the document to the FOI applicant. **Please note** that it is not sufficient to simply to take a blanket approach in stating that the documents are exempt in full. It would be beneficial to identify *specific information* which you consider to be exempt. That is the information should be clearly marked and identified (preferably in a highlighted version), along with specific and adequate justification for the objection. Please explain why the information is exempt and describe what, if any, effects will be caused if the information is released. Further, TGA is unlikely to exempt information that is in the public domain.

Please note that subsection 11B(4) of the FOI Act states that the FOI decision maker is not required to consider certain irrelevant factors when assessing your consultation response. These include:

- access to the document could result in any person misinterpreting or misunderstanding the document; and
- access to the document could result in confusion or unnecessary debate.

As stated in the attachment, your response would be appreciated by **COB Tuesday, 5 May 2026**.

Unless you advise otherwise, please note that the TGA will not be consulting with the relevant manufacturers with regard to this matter, however please let us know if you wish for the TGA to consult them separately.

Should you require more time to provide a response please let us know at your earliest convenience.

Please confirm receipt of this email and the attached documents when received, and please feel free to contact the TGA FOI team if you have any questions.

Kind regards

s22

Freedom of Information



Therapeutic Goods Administration
Australian Government Department of Health, Disability and Ageing
Address: PO Box 100, Woden ACT, 2606, Australia

E: TGAFOI@tga.gov.au

T: + 61 2 6289 4630

Important: *This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission.*

OFFICIAL

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

From: [TGA FOI](#)
To: s22 @s47G
Cc: [TGA FOI](#); s47G
Subject: FOI 26-2918 - Notice of Decision [SEC=OFFICIAL]
Date: Wednesday, 27 May 2026 6:57:38 PM
Attachments: [FOI 26-2918 - Notice of Decision - Maxx Pharma Pty Ltd.pdf](#)
[Document 1 MR.PDF](#)
[ATTACHMENT B - Decision letter.PDF](#)

OFFICIAL

Dear Ms s22

Please find attached correspondence in relation to a Freedom of Information request which Maxx Pharma Pty Ltd were consulted on.

Publication.

Under section 11C of the FOI Act, the TGA must publish documents released under the FOI Act on its Disclosure Log, unless it would be unreasonable to do so. Further information about the disclosure log can be found at <https://www.tga.gov.au/foi-disclosure-log>.

If you have any questions, please do not hesitate to contact the FOI Team.

Kind regards

s22

Freedom of Information



Therapeutic Goods Administration
Australian Government Department of Health, Disability and Ageing
Address: PO Box 100, Woden ACT, 2606, Australia

E: TGAFOI@tga.gov.au

T: + 61 2 6289 4630

Important: *This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission.*

OFFICIAL